Whole body hyperthermia

A phase-1 trial of a potential adjuvant to chemotherapy

J. M. Bull, D. Lees, W. Schuette, J. Whang-Peng, R. Smith, G. Bynum, E. R. Atkinson, J. S. Gottdiener, H. R. Gralnick, T. H. Shawker, V. T. DeVita

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Fourteen patients with a variety of neoplasms not responsive to standard forms of therapy underwent whole body hyperthermia for a maximum 4 h at 41.8°C. This was a phase-1 cancer trial designed to develop whole body hyperthermia as an adjuvant to systemic chemotherapy. Intravenous analgesia was used to sedate patients, obviating the need for general endotracheal anesthesia. Hyperthermia was induced by means of a high-flow water perfusion suit. Cardiovascular performance was evaluated using a flow-directed pulmonary artery catheter. Patients developed a twofold mean increase in cardiac index without evidence of cardiac damage by ECG or creatine phosphokinase (CPK) isoenzymes. An acute fall in serum magnesium and phosphate and an acute rise in arterial pH, serum CPK values, and granulocyte count occurred in all patients. There were no clotting abnormalities. Toxicity included fatigue, diarrhea, nausea, and transient elevations in liver enzymes. Four patients were febrile for 36 h after initial defervescence. Peripheral neuropathy developed in four. These results show that with carefully monitored conditions whole body hyperthermia is feasible.

Original languageEnglish
Pages (from-to)317-323
Number of pages7
JournalAnnals of Internal Medicine
Volume90
Issue number3
Publication statusPublished - Aug 6 1979
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Fever
Creatine Kinase
Endotracheal Anesthesia
Induced Hyperthermia
Peripheral Nervous System Diseases
Serum
Granulocytes
Analgesia
General Anesthesia
Nausea
Pulmonary Artery
Isoenzymes
Fatigue
Diarrhea
Neoplasms
Electrocardiography
Catheters
Perfusion
Drug Therapy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Bull, J. M., Lees, D., Schuette, W., Whang-Peng, J., Smith, R., Bynum, G., ... DeVita, V. T. (1979). Whole body hyperthermia: A phase-1 trial of a potential adjuvant to chemotherapy. Annals of Internal Medicine, 90(3), 317-323.

Whole body hyperthermia : A phase-1 trial of a potential adjuvant to chemotherapy. / Bull, J. M.; Lees, D.; Schuette, W.; Whang-Peng, J.; Smith, R.; Bynum, G.; Atkinson, E. R.; Gottdiener, J. S.; Gralnick, H. R.; Shawker, T. H.; DeVita, V. T.

In: Annals of Internal Medicine, Vol. 90, No. 3, 06.08.1979, p. 317-323.

Research output: Contribution to journalArticle

Bull, JM, Lees, D, Schuette, W, Whang-Peng, J, Smith, R, Bynum, G, Atkinson, ER, Gottdiener, JS, Gralnick, HR, Shawker, TH & DeVita, VT 1979, 'Whole body hyperthermia: A phase-1 trial of a potential adjuvant to chemotherapy', Annals of Internal Medicine, vol. 90, no. 3, pp. 317-323.
Bull JM, Lees D, Schuette W, Whang-Peng J, Smith R, Bynum G et al. Whole body hyperthermia: A phase-1 trial of a potential adjuvant to chemotherapy. Annals of Internal Medicine. 1979 Aug 6;90(3):317-323.
Bull, J. M. ; Lees, D. ; Schuette, W. ; Whang-Peng, J. ; Smith, R. ; Bynum, G. ; Atkinson, E. R. ; Gottdiener, J. S. ; Gralnick, H. R. ; Shawker, T. H. ; DeVita, V. T. / Whole body hyperthermia : A phase-1 trial of a potential adjuvant to chemotherapy. In: Annals of Internal Medicine. 1979 ; Vol. 90, No. 3. pp. 317-323.
@article{44c9a2e1426f470ba73ade0a7a9766c9,
title = "Whole body hyperthermia: A phase-1 trial of a potential adjuvant to chemotherapy",
abstract = "Fourteen patients with a variety of neoplasms not responsive to standard forms of therapy underwent whole body hyperthermia for a maximum 4 h at 41.8°C. This was a phase-1 cancer trial designed to develop whole body hyperthermia as an adjuvant to systemic chemotherapy. Intravenous analgesia was used to sedate patients, obviating the need for general endotracheal anesthesia. Hyperthermia was induced by means of a high-flow water perfusion suit. Cardiovascular performance was evaluated using a flow-directed pulmonary artery catheter. Patients developed a twofold mean increase in cardiac index without evidence of cardiac damage by ECG or creatine phosphokinase (CPK) isoenzymes. An acute fall in serum magnesium and phosphate and an acute rise in arterial pH, serum CPK values, and granulocyte count occurred in all patients. There were no clotting abnormalities. Toxicity included fatigue, diarrhea, nausea, and transient elevations in liver enzymes. Four patients were febrile for 36 h after initial defervescence. Peripheral neuropathy developed in four. These results show that with carefully monitored conditions whole body hyperthermia is feasible.",
author = "Bull, {J. M.} and D. Lees and W. Schuette and J. Whang-Peng and R. Smith and G. Bynum and Atkinson, {E. R.} and Gottdiener, {J. S.} and Gralnick, {H. R.} and Shawker, {T. H.} and DeVita, {V. T.}",
year = "1979",
month = "8",
day = "6",
language = "English",
volume = "90",
pages = "317--323",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Whole body hyperthermia

T2 - A phase-1 trial of a potential adjuvant to chemotherapy

AU - Bull, J. M.

AU - Lees, D.

AU - Schuette, W.

AU - Whang-Peng, J.

AU - Smith, R.

AU - Bynum, G.

AU - Atkinson, E. R.

AU - Gottdiener, J. S.

AU - Gralnick, H. R.

AU - Shawker, T. H.

AU - DeVita, V. T.

PY - 1979/8/6

Y1 - 1979/8/6

N2 - Fourteen patients with a variety of neoplasms not responsive to standard forms of therapy underwent whole body hyperthermia for a maximum 4 h at 41.8°C. This was a phase-1 cancer trial designed to develop whole body hyperthermia as an adjuvant to systemic chemotherapy. Intravenous analgesia was used to sedate patients, obviating the need for general endotracheal anesthesia. Hyperthermia was induced by means of a high-flow water perfusion suit. Cardiovascular performance was evaluated using a flow-directed pulmonary artery catheter. Patients developed a twofold mean increase in cardiac index without evidence of cardiac damage by ECG or creatine phosphokinase (CPK) isoenzymes. An acute fall in serum magnesium and phosphate and an acute rise in arterial pH, serum CPK values, and granulocyte count occurred in all patients. There were no clotting abnormalities. Toxicity included fatigue, diarrhea, nausea, and transient elevations in liver enzymes. Four patients were febrile for 36 h after initial defervescence. Peripheral neuropathy developed in four. These results show that with carefully monitored conditions whole body hyperthermia is feasible.

AB - Fourteen patients with a variety of neoplasms not responsive to standard forms of therapy underwent whole body hyperthermia for a maximum 4 h at 41.8°C. This was a phase-1 cancer trial designed to develop whole body hyperthermia as an adjuvant to systemic chemotherapy. Intravenous analgesia was used to sedate patients, obviating the need for general endotracheal anesthesia. Hyperthermia was induced by means of a high-flow water perfusion suit. Cardiovascular performance was evaluated using a flow-directed pulmonary artery catheter. Patients developed a twofold mean increase in cardiac index without evidence of cardiac damage by ECG or creatine phosphokinase (CPK) isoenzymes. An acute fall in serum magnesium and phosphate and an acute rise in arterial pH, serum CPK values, and granulocyte count occurred in all patients. There were no clotting abnormalities. Toxicity included fatigue, diarrhea, nausea, and transient elevations in liver enzymes. Four patients were febrile for 36 h after initial defervescence. Peripheral neuropathy developed in four. These results show that with carefully monitored conditions whole body hyperthermia is feasible.

UR - http://www.scopus.com/inward/record.url?scp=0018342509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018342509&partnerID=8YFLogxK

M3 - Article

VL - 90

SP - 317

EP - 323

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -